Use of cannabidiol prodrugs in topical and transdermal administration with microneedles
AssigneeZynerba Pharmaceuticals, Inc.
InventorsAudra Lynn Stinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffery Lynn Howard, Dana Carmel Hammell
Life of this patent
Estimating the term…
Abstract
Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.
Claims16
A microneedle drug delivery system for transdermal or topical administration of a cannabidiol prodrug to a mammal comprising:
- (a) a pharmaceutical composition in the form of a hydrogel comprising
- (i) about 0.1% to about 40% of cannabidiol prodrug:
- where X− is a counter ion derived from pharmaceutically acceptable acids,
- (ii) about 0.1% to about 20% of one or more co-solvents;
- (iii) about 15% to about 95% a lower alcohol;
- and
- (iv) water in a quantity sufficient for the composition to total 100% (wt/wt);
- (b) a microneedle array;
- and
- (c) a matrix- or reservoir-type patch incorporating at least the pharmaceutical composition and the microneedle array.
Dependencies are inferred from the claim text.